The effect of vitamin D levels on the course of COVID-19 in hospitalized patients – a 1-year prospective cohort study [version 1; peer review: awaiting peer review]

Siuka, Darko (avtor), Saletinger, Rajko (avtor), Uršič, Jure (avtor), Jevnikar, Kristina (avtor), Janša, Rado (avtor), Štubljar, David (avtor), Osredkar, Joško (avtor)

Background: The aim of the current study was to assess the patients with COVID-19 and the impact of vitamin D supplementation on the course of COVID-19. Methods: This prospective cohort study included patients hospitalized due to COVID-19 between December 2020 and December 2021. Patients' demographic, clinical, and laboratory parameters were analysed. Results: 301 participants were enrolled in the study. 46 (15,3%) had moderate, and 162 (53,8%) had severe COVID-19. 14 (4,7%) patients died, and 30 (10,0%) were admitted to the ICU due to disease worsening. The majority needed oxygen therapy (n=224; 74,4%). Average vitamin 25(OH)D3 levels were below optimal at the admittance, and vitamin D deficiency was detected in 205 individuals. More male patients were suffering from vitamin D deficiency. Patients with the more severe disease showed lower levels of vitamin 25(OH)D3 in their blood. The most severe group of patients had more symptoms that lasted significantly longer with progressing disease severity. This group of patients also suffered from more deaths, ICU admissions, and treatments with dexamethasone, remdesivir, and oxygen. Conclusion: Patients with the severe course of COVID-19 were shown to have increased inflammatory parameters, increased mortality, and higher incidence of vitamin D deficiency. The results suggest that the vitamin D deficiency might represent a significant risk factor for a severe course of COVID-19.

• Jezik: Angleški jezik
• Ključne besede: vitamin D, COVID-19, severity, supplementation, dexamethasone, remdesivir
• Vrsta gradiva: Članek v reviji
• Tipologija: 1.01 - Izvirni znanstveni članek
• Organizacija: FFA - Fakulteta za farmacijo ; MF - Medicinska fakulteta
• Status publikacije: Objavljeno
• Različica publikacije: Objavljena publikacija
• Leto izida: 2023
• Št. strani: 15 str.
• Številčenje: art. 254, Vol. 12
• PID: 20.500.12556/RUL-144741
• UDK: 577.161.2
• ISSN pri članku: 2046-1402
• DOI: 10.12688/f1000research.131730.1
• COBISS.SI-ID: 144681219
• Datum objave v RUL: 10.03.2023

Gradivo je del revije

• Naslov: F1000Research
• Skrajšan naslov: F1000Research
• Založnik: F1000Research
• ISSN: 2046-1402
• COBISS.SI-ID: 31416537

Licence

• Licenca: CC BY 2.0, Creative Commons Priznanje avtorstva 2.0 Generična
• Povezava: https://creativecommons.org/licenses/by/2.0/deed.sl
• Opis: Dovoljuje kopiranje in razširjanje vsebin v kakršnemkoli mediju in obliki. Dovoljuje remixanje, urejanje, predelava in vključevanje vsebine v lastna dela v vse namene, tudi komercialne. Primerno morate navesti avtorja, povezavo do licence in označiti spremembe, če so kakšne nastale. To lahko storite na kakršenkoli razumen način, vendar ne na način, ki bi namigoval na to, da dajalec licence podpira vas ali vašo uporabo dela. Ne smete uporabiti pravnih določil ali tehničnih ukrepov, ki bi pravno omejili ali onemogočilo druge, da bi storili karkoli, kar licenca dovoli.

Sekundarni jezik

• Jezik: Slovenski jezik
• Ključne besede: resnost, dopolnjevanje, deksametazon, emdesivir, COVID-19, vitamin D